Rounding out its antibody and small molecule drug alliances, Oxford GlycoSciences has coupled with Swedish antibody manufacturer BioInvent in a deal that provides OGS with access to phage display technology for producing antibodies to its protein targets, and BioInvent with $5 million in equity financing Subscribers: click headline for more.
After helping start several companies while at the Stanford Research Institute, Luke Schneider finally decided five years ago that it was time to go out and do his own thing Subscribers: click headline for more.
Shimadzu Biotech expects to open a new center for protein analysis in the Tokyo suburb of Tsukuba by October this year, the company s chairman, Tetsuo Ichikawa, told ProteoMonitor last week Subscribers: click headline for more.
While it s a fairly widely held assumption that a protein analysis and identification facility should include a range of both high- and low-end mass spectrometers, the constantly shifting seas of mass spectrometry technology can sometimes create quandaries for proteomics researchers seeking to find the right balance between price, reliability, and optimal performance. Subscribers: click headline for more.
Given the steadily rising interest in proteomics on the part of the life science community, it may not be surprising that a number of professional scientific societies have tried to broaden their appeal to scientists using such techniques as 2D gels and mass spectrometry in their studies of proteins. Subscribers: click headline for more.
Promising to alleviate some of the shortcomings of 2D gels, Lynx Therapeutics is developing a two-dimensional microchannel electrophoresis system that may reverse -- quite literally -- a few conventions in the process Subscribers: click headline for more.
Continuing its trend of doing business with suppliers who make equity investments, GeneProt last week announced it had signed an agreement with Zymark to buy four of its automated protein digestion and spotting systems Subscribers: click headline for more.
Zyomyx is off for a check-up with a diagnostics specialist: Last week, the Hayward, California-based protein chip maker said it would grant Specialty Laboratories, which offers and develops specialized clinical tests, early access to its protein biochip platform to find diagnostic protein patterns Subscribers: click headline for more.
The challenge of getting the right formula for surface chemistry on a chip has frustrated many would-be array makers in the protein arena. How do you immobilize the ligands without allowing nonspecific binding of proteins to the chip Subscribers: click headline for more.